Lisinopril Tablet
Description
SIPROOT-5
Lisinopril Tablets
Division: DIABGLYM
Composition
Each tablet contains:
Lisinopril IP — 5 mg
Excipients — q.s.
Colour: Approved colour used
Dosage form: Oral tablet
Product Description
SIPROOT-5 contains Lisinopril 5 mg, an angiotensin-converting enzyme (ACE) inhibitor widely prescribed for the management of hypertension, heart failure, and cardiovascular risk reduction. Lisinopril works by inhibiting the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor, thereby promoting vasodilation, reducing blood pressure, decreasing cardiac workload, and improving cardiovascular outcomes.
Lisinopril is one of the most extensively studied ACE inhibitors and is recommended in several international treatment guidelines for hypertension, chronic heart failure, post-myocardial infarction management, and diabetic nephropathy. It provides effective 24-hour blood pressure control and helps protect target organs such as the heart and kidneys.
SIPROOT-5 is particularly beneficial in patients with hypertension associated with diabetes, chronic kidney disease, left ventricular dysfunction, or cardiovascular disease. Regular therapy helps reduce the risk of stroke, myocardial infarction, heart failure progression, and renal complications.
Technical Knowledge of Lisinopril
Lisinopril is a long-acting ACE inhibitor that does not require hepatic activation and is active in its administered form. It inhibits ACE, resulting in reduced angiotensin II levels and decreased aldosterone secretion. This leads to vasodilation, reduced sodium and water retention, improved renal blood flow, and decreased preload and afterload on the heart.
Mechanism of Action
Lisinopril inhibits angiotensin-converting enzyme, reduces angiotensin II production, decreases peripheral vascular resistance, lowers aldosterone secretion, reduces sodium and fluid retention, improves endothelial function, and provides cardiovascular and renal protection.
Key Benefits
Effective control of hypertension
Provides 24-hour blood pressure reduction
Reduces cardiovascular morbidity and mortality
Improves outcomes in heart failure
Protects renal function in diabetic patients
Reduces progression of diabetic nephropathy
Decreases the risk of stroke and myocardial infarction
Suitable for long-term cardiovascular management under medical supervision
Clinical Applications
SIPROOT-5 is commonly prescribed for hypertension, chronic heart failure, post-myocardial infarction therapy, diabetic nephropathy, chronic kidney disease with proteinuria, cardiovascular risk reduction, and left ventricular dysfunction.
Facts About Lisinopril
Lisinopril is an evidence-based ACE inhibitor with extensive clinical use worldwide. It is effective as monotherapy and in combination with other antihypertensive agents. It has a long duration of action, allowing convenient once-daily dosing. ACE inhibitors are considered first-line therapy in many patients with hypertension and diabetes due to their renal protective effects.
Key Facts
ACE inhibitor with proven cardiovascular benefits
Long-acting once-daily antihypertensive therapy
Provides renal protection in diabetic patients
Reduces cardiac workload and vascular resistance
Evidence-supported therapy for heart failure and post-MI management
Quality-assured pharmaceutical formulation
PCD Pharma Franchise Opportunity
SIPROOT-5 is an excellent product for PCD Pharma Franchise, Cardiology Franchise, and Diabetology Franchise across India. The increasing prevalence of hypertension, diabetes, cardiovascular disease, and kidney disorders creates strong prescription demand and long-term market potential for this formulation.
Why Choose SIPROOT-5 for PCD Pharma Franchise?
High prescription potential
Strong physician and cardiologist acceptance
Attractive monopoly franchise opportunity
Competitive pricing
Promotional support available
Visual aids and marketing inputs
Consistent product quality
Excellent repeat business potential
Third Party Manufacturing
Chemsroot Pharmaceutical offers Third Party Manufacturing of Lisinopril Tablets with complete manufacturing support for pharmaceutical companies, marketers, exporters, and franchise businesses.
Our Third Party Manufacturing Services Include
Private label manufacturing
Contract manufacturing
Custom brand manufacturing
Loan license manufacturing
DCGI-compliant production
GMP-certified manufacturing
Batch manufacturing documentation
Product registration support
Customized packaging and artwork
Monopoly franchise packaging
Bulk manufacturing capability
Manufacturing Features
Pharmaceutical-grade raw materials
IP/BP/USP quality standards
In-process quality control
Finished product testing
Stability-oriented formulation
Moisture-controlled tablet manufacturing
Blister and Alu-Alu packaging options
SIPROOT-5 from DIABGLYM combines effective blood pressure control, cardiovascular protection, renal safety, and high-quality pharmaceutical manufacturing, making it an ideal product for physicians, cardiologists, diabetologists, PCD Pharma Franchise partners, and Third Party Manufacturing clients seeking a reliable and evidence-based Lisinopril formulation.
